Mavacamten is a small-molecule cardiac myosin inhibitor used to treat symptomatic obstructive hypertrophic cardiomyopathy by reducing myocardial contractility and relieving left ventricular outflow tract… Read more









![Chemical structure of (S)-N-(1',3-Diisopropyl-2,2',4,6'-tetraoxo-1',2',3,3',4,6'-hexahydro-2H-[1,4'-bipyrimidin]-6-yl)-N-(1-phenylethyl)nitrous amide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FS-N-13-Diisopropyl-2246-tetraoxo-123346-hexahydro-2H-14-bipyrimidin-6-yl-N-1-phenylethylnitrous-amide.png&w=3840&q=75)








































Mavacamten is a small-molecule cardiac myosin inhibitor used to treat symptomatic obstructive hypertrophic cardiomyopathy by reducing myocardial contractility and relieving left ventricular outflow tract obstruction. This category contains a comprehensive range of high-quality analytical reference standards, including the active pharmaceutical ingredient, its known impurities, related metabolites such as glucuronides, and stable isotope-labeled compounds. Pharmaceutical laboratories utilize these materials for rigorous impurity profiling, method development, and validation to ensure the potency, safety, and stability of the drug substance. By providing essential tools for precise analytical testing and quality control, these reference standards allow for the identification and quantification of degradation products and synthetic by-products throughout the manufacturing and regulatory compliance process.